Shares of Cybin Inc. (OTCMKTS:CYBN – Get Free Report) fell 2% during trading on Wednesday . The stock traded as low as $8.65 and last traded at $8.82. 209,562 shares were traded during mid-day trading, an increase of 9% from the average session volume of 191,388 shares. The stock had previously closed at $9.00.
Cybin Stock Down 2.0 %
The business has a 50-day simple moving average of $10.26 and a two-hundred day simple moving average of $5.38. The stock has a market capitalization of $176.33 million, a P/E ratio of -46.42 and a beta of 0.39.
Cybin Company Profile
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Featured Stories
- Five stocks we like better than Cybin
- Golden Cross Stocks: Pattern, Examples and Charts
- Work and Play: Investing in the Rise of Bleisure Travel
- Find and Profitably Trade Stocks at 52-Week Lows
- Top Dividend Stocks to Buy Now as Bond Yields Could Lower
- Bank Stocks – Best Bank Stocks to Invest In
- SAP: AI Tailwinds Accelerating Enterprise Cloud Business
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
